The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
There wont be any concrete orders until the CE Mark is awarded and partnerships take time to develop. This is a long term opportunity so buy to average down but not in the hope of a big rise in the SP from Esska. I've exhibited at many shows and its an educational process.
There will be nothing until the results for FY to Mar 31st. Based on last year they will come out early June. As for Chondromimetic we won't see any actual sales for some time as they have to apply for a CE mark. See this statement from the company: Collagen Solutions has started the submission process to re-establish the CE Mark for ChondroMimetic�. Following finalisation of the clinical study report, supplemental data will be submitted to complete the submission and support CE Mark approval, targeted for the second half of 2018. Note "second half of 2018" So this is for the LONG term.
Trade wars not good!
They didn't develop it - they bought the IP
Hardman research is paid for by the company so independent research is more credible, esp for sales forecasts
Tunga in cheek methinks
This news is more than positive its almost a total cure and it performs better than more expensive treatments. Data highlights � Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage. � Improvement in patient clinical symptoms, including pain, function and activity level after treatment sustained over the eight-year period. � The 'Knee Injury and Osteoarthritis Outcome Score' (KOOS), a well-known and validated patient reported outcome measure, showed outcomes following the ChondroMimetic� procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies. Backed by these results ChondroMimetic� is positioned as the only minimally invasive, cost-effective, single-stage treatment that fits within surgeons' current surgical techniques for smaller cartilage defects with eight-year clinical effectiveness and repair quality data.
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine, including orthopaedic, dental, wound care, and cardiovascular applications
This company is NOT a beauty product company.
The same as always - more sellers than buyers.
And that's without a war.
Probably the Telegraph tip today
Why do you think they would sign an agreement BEFORE the results of the final patient follow up come out in 3 months? Have they has a "Korean whisper" that it's good news? PS if this makes no sense look up "Chinese whisper"
Just had a look at the Market Capitalization. This is the value of all the shares in issue. It is �10.79 million The company's assets are �20.29 million We could easily see a doubling of the price. Half year results on Dec 5th with the bad news already out there. There's only one way it can go :-)
You have this wrong. Cash in the bank accounts for 65% of the share price.
Calm before............
My prophecy yesterday fulfilled: 100000 bought next day and the price up
It's all to do with volumes. All you need is a couple of sells to cause a drop. If you were to buy 50-75 000 tomorrow the price will rise. The action will start when the rescan results are published, progress on a CE mark shows and the results come in.
"an arrangement whereby access is restricted to users who have paid to subscribe to the site"
Worked out well in "The Deerhunter"